939
Views
23
CrossRef citations to date
0
Altmetric
Original Article : Clinical

Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children’s Oncology Group AALL07P4*

, , ORCID Icon, , , , , , & show all
Pages 1740-1748 | Received 27 Jun 2018, Accepted 23 Oct 2018, Published online: 10 Jan 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Melissa Sandley & Jonathan Angus. (2023) Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management. Leukemia & Lymphoma 64:4, pages 776-787.
Read now
Cynthia Bender, Luke Maese, Maria Carter-Febres & Anupam Verma. (2021) Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood and Lymphatic Cancer: Targets and Therapy 11, pages 25-40.
Read now
Carmen Hernández-Marqués, Maitane Andión, Marta Perez-Somarriba, Luis Madero & Alvaro Lassaletta. (2020) Can monitoring asparaginase activity help us to manage toxicity in pediatric acute lymphoblastic leukemia?. Leukemia & Lymphoma 61:4, pages 990-992.
Read now
Benjamin A. Derman, Mitchell Streck, Joseph Wynne, Trevor N. Christ, Emily Curran, Wendy Stock & Randall W. Knoebel. (2020) Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia & Lymphoma 61:3, pages 614-622.
Read now
Paul S. Gaynon. (2019) Methotrexate and asparaginase: not so simple. Leukemia & Lymphoma 60:12, pages 2849-2850.
Read now
Bernard L. Marini, Julia Brown, Lydia Benitez, Emily Walling, Raymond J. Hutchinson, Rajen Mody, Rama Jasty Rao, Lynn Slagle, Lauren Bishop, Kristen Pettit, Dale L. Bixby, Patrick W. Burke & Anthony J. Perissinotti. (2019) A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leukemia & Lymphoma 60:12, pages 2854-2868.
Read now

Articles from other publishers (17)

Renato Bassan, Sabina Chiaretti, Irene Della Starza, Orietta Spinelli, Alessandra Santoro, Francesca Paoloni, Monica Messina, Loredana Elia, Maria Stefania De Propris, Anna Maria Scattolin, Ernesta Audisio, Laura Marbello, Erika Borlenghi, Patrizia Zappasodi, Elisa Mauro, Giovanni Martinelli, Daniele Mattei, Nicola Fracchiolla, Monica Bocchia, Paolo De Fabritiis, Massimiliano Bonifacio, Anna Candoni, Vincenzo Cassibba, Paolo Di Bartolomeo, Giancarlo Latte, Silvia Trappolini, Anna Guarini, Antonella Vitale, Paola Fazi, Alfonso Piciocchi, Alessandro Rambaldi & Robin Foà. (2023) Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Advances 7:16, pages 4448-4461.
Crossref
Taylor D. Coe-Eisenberg, Anthony J. Perissinotti, Bernard L. Marini, Kristen M. Pettit, Dale L. Bixby, Patrick W. Burke & Lydia Benitez. (2023) Evaluating the efficacy and toxicity of dose adjusted pegylated L-asparaginase in combination with therapeutic drug monitoring. Annals of Hematology.
Crossref
Suja Johnson, Chetan Dhamne, Hari Sankaran, Khushboo A. Gandhi, Pallavi Rane, Nirmaly Roy Moulik, Shraddha Mahesh Jadhav, Murari Gurjar, Gaurav Narula, Shripad Banavali & Vikram Gota. (2022) A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL). Cancer Chemotherapy and Pharmacology 90:6, pages 445-453.
Crossref
Daiane Keller Cecconello, Ciliana Rechenmacher, Klerize Anecely de Souza Silva, Fernanda Fetter Scherer, Thomas Dal Bem Prates, Rebeca Ferreira Marques, Liane Esteves Daudt & Mariana Bohns Michalowski. (2022) Follow our path with asparaginase activity: one technique, but different uses in clinical practice. Experimental Hematology & Oncology 11:1.
Crossref
Jasmeet Sidhu, Ashish Narayan Masurekar, Manash Pratim Gogoi, Caroline Fong, Tasos Ioannou, Taha Lodhi, Catriona Parker, Jizhong Liu, Amy A. Kirkwood, Anthony V. Moorman, Kiranmoy Das, Nicholas J. Goulden, Ajay Vora, Vaskar Saha & Shekhar Krishnan. (2022) Activity and toxicity of intramuscular 1000 iu /m 2 polyethylene glycol‐ E. coli L‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials . British Journal of Haematology 198:1, pages 142-150.
Crossref
Luke Maese & Rachel E. Rau. (2022) Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Frontiers in Pediatrics 10.
Crossref
Dan Douer, Nicola Gökbuget, Wendy Stock & Nicolas Boissel. (2022) Optimizing use of L-asparaginase–based treatment of adults with acute lymphoblastic leukemia. Blood Reviews 53, pages 100908.
Crossref
Maaike Van Trimpont, Evelien Peeters, Yanti De Visser, Amanda M. Schalk, Veerle Mondelaers, Barbara De Moerloose, Arnon Lavie, Tim Lammens, Steven Goossens & Pieter Van Vlierberghe. (2022) Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy. Cancers 14:4, pages 902.
Crossref
Tapasvi Modi & David Gervais. (2021) Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase. Investigational New Drugs 40:1, pages 21-29.
Crossref
Meghan McCormick, Jillian Lapinski, Erika Friehling & Kenneth Smith. (2021) Premedication prior to PEG‐asparaginase is cost‐effective in pediatric patients with acute lymphoblastic leukemia. Pediatric Blood & Cancer 68:8.
Crossref
Federico Lussana, Paola Minetto, Felicetto Ferrara, Sabina Chiaretti, Giorgina Specchia & Renato Bassan. (2020) National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. BMC Cancer 20:1.
Crossref
Yunze Zhao, Zhigang Li, Li Zhang, Hongyun Lian, Honghao Ma, Dong Wang, Xiaoxi Zhao, Qing Zhang, Tianyou Wang & Rui Zhang. (2020) L‐DEP regimen salvage therapy for paediatric patients with refractory Epstein‐Barr virus‐associated haemophagocytic lymphohistiocytosis. British Journal of Haematology 191:3, pages 453-459.
Crossref
Gudrun WürthweinClaudia Lanvers-KaminskyJoachim GerssAnja MörickeMartin ZimmermannJan StaryPetr SmisekAndishe AttarbaschiChrista NathMassimo Zucchetti, Carmelo RizzariMartin SchrappeJoachim Boos. (2020) Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study. Therapeutic Drug Monitoring 42:3, pages 435-444.
Crossref
Komail Nadeem, David Colantonio, Ida Kircanski, Ahmed Naqvi, Johann Hitzler, James A. Whitlock & L. Lee Dupuis. (2019) Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single‐center study. Pediatric Blood & Cancer 67:2.
Crossref
Francesca Carobolante, Sabina Chiaretti, Cristina Skert & Renato Bassan. (2020) Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. Therapeutic Advances in Hematology 11, pages 204062072090353.
Crossref
Linda Cerofolini, Marco Fragai, Enrico Ravera, Christoph A. Diebolder, Ludovic Renault & Vito Calderone. (2019) Integrative Approaches in Structural Biology: A More Complete Picture from the Combination of Individual Techniques. Biomolecules 9:8, pages 370.
Crossref
Michael Losasso, Bruce Bostrom & Yoav Messinger. (2020) Retrospective cohort study monitoring PEG-asparaginase activity in acute lymphoblastic leukemia patients with and without premedication. F1000Research 8, pages 1007.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.